Chromadex Corp. Stock Plummets to New 52-Week Low of $3.27

Chromadex Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.27 as of June 29, 2026. This significant decline highlights the company's struggles in a competitive market, particularly as it has underperformed relative to the S&P 500, which has seen a return of 20.53% over the past year. In contrast, Chromadex has experienced a notable drop of 75.25% during the same period. Despite the challenges, Chromadex maintains a market capitalization of USD 336 million and a price-to-earnings ratio of 19.00. The company has demonstrated a return on equity of 22.71%, indicating some level of profitability, although its average return on equity over the past year was lower at 5.86%. The stock's price-to-book ratio stands at 4.39, suggesting an attractive valuation relative to its book value. Additionally, Chromadex has a high institutional ownership of 51.28%, reflecting confidence from larger investors, even as the company navigates its current market position.